Transgenic Mouse Model for Tau Oligomer Visualization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a reliable experimental approach to specifically detect tau oligomers in the early stages of aggregation within the brain, hindering the understanding and monitoring of tau oligomer formation and its role in neurodegenerative diseases.
Innovation Solution
A transgenic mouse model is developed using a vector pair that employs the bimolecular fluorescence complementation (BiFC) technique, allowing for the visualization of tau oligomer formation through fluorescence, enabling direct detection and monitoring of tau oligomers in the brain and facilitating the screening of inhibitor candidates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If immunotherapeutic technology using tau antibodies is used to detect tau aggregates, then tau aggregates can be detected in neurons, but the method cannot specifically distinguish tau oligomers in the early stage of aggregation from normal tau protein present in large amounts
Solution Approach 1:
The invention divides the detection task into two segments: first, tau protein is segmented into oligomeric and non-oligomeric forms; second, the detection system is segmented into BiFC-based oligomer detection and antibody-based aggregate detection. This segmentation allows specific detection of tau oligomers despite the presence of large amounts of normal tau protein, resolving the contradiction between measurement precision and quantity of substance.
Solution Approach 2:
The invention introduces an intermediary detection system based on BiFC (bimolecular fluorescence complementation) that acts as a mediator between tau oligomers and detection methods. The BiFC system specifically binds to tau oligomers through its molecular recognition mechanism, enabling specific detection without being interfered by normal tau protein background, thus resolving the detection specificity issue.
2Measurement precision
If biochemical experimental techniques are used for isolation and identification of tau oligomers, then some tau oligomers can be identified, but direct observation of tau oligomers in the brain has not yet been reported
Solution Approach 1:
The invention replaces complex biochemical experimental techniques with a simplified optical detection system based on BiFC. This substitution eliminates the need for complex sample preparation and biochemical analysis, enabling direct observation of tau oligomers in brain tissue through fluorescence imaging, thus resolving the contradiction between measurement precision and detection difficulty.
Solution Approach 2:
The invention utilizes fluorescence color changes as a visual indicator of tau oligomer formation. The BiFC system produces fluorescent signals specifically when tau oligomers are present, allowing direct observation and visualization of tau oligomers in brain tissue without complex biochemical procedures, thereby resolving the detection difficulty while maintaining high measurement precision.
3Productivity
If cell models enabling real-time monitoring of tau aggregation mechanisms are developed, then tau aggregation can be monitored in living cells, but technology development is still insufficient
Solution Approach 1:
The invention creates a universal transgenic mouse model that can monitor multiple aspects of tau aggregation simultaneously through the BiFC system. The model can detect tau oligomer formation, track aggregation progression, and evaluate therapeutic interventions in real-time within the same living animal, providing multi-functional capability that justifies the initial construction complexity while delivering high productivity in research applications.
Solution Approach 2:
The invention performs preliminary action by constructing the transgenic mouse model with BiFC-based tau oligomer detection capability before conducting research studies. This preliminary model construction enables all subsequent real-time monitoring experiments to be conducted efficiently without needing to develop new detection methods for each study, thereby resolving the contradiction between real-time monitoring capability and device complexity across multiple research applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables real-time visualization and quantification of tau oligomer formation in the brain, providing a valuable tool for investigating tau pathology and discovering therapeutic agents for neurodegenerative diseases such as dementia.
Implementation Method 1
A transgenic mouse model is developed using a vector pair that employs the bimolecular fluorescence complementation (BiFC) technique, allowing for the visualization of tau oligomer formation through fluorescence
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3~4
AI summary
The present invention relates to a vector pair for screening tau oligomer formation, a mouse embryo introduced with the vector pair, a transgenic model mouse of neurological disease, obtained from the mouse embryo, and a method of screening a tau oligomer formation inhibitor candidate using the transgenic model mouse. More specifically, the present invention provides vector pair for screening tau oligomer formation, comprising: a first vector comprising a first tau gene, a first fluorescence protein gene and a first neuron-specific promoter; and a second vector comprising a second tau gene, a second fluorescence protein gene and a second neuron-specific promoter, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first tau gene and a protein expressed from the second tau gene.